Patients with chronic hepatitis C achieving a sustained virological response to peginterferon and ribavirin therapy recover from impaired hepcidin secretion.
about
Chronic hepatitis C and liver fibrosis.Interferon lambda polymorphisms associate with body iron indices and hepatic expression of interferon-responsive long non-coding RNA in chronic hepatitis C.Mass spectrometry measurement of plasma hepcidin for the prediction of iron overload.Successful antiviral therapy is associated with a decrease of serum prohepcidin in chronic hepatitis C.Hepcidin expression in iron overload diseases is variably modulated by circulating factorsIron regulator hepcidin exhibits antiviral activity against hepatitis C virus.Hepatitis B and C virus hepatocarcinogenesis: lessons learned and future challenges.Association of hepcidin mRNA expression with hepatocyte iron accumulation and effects of antiviral therapy in chronic hepatitis C infection.Branched-chain amino acid supplementation reduces oxidative stress and prolongs survival in rats with advanced liver cirrhosisBranched-chain amino acids reduce hepatic iron accumulation and oxidative stress in hepatitis C virus polyprotein-expressing miceMinihepcidins are rationally designed small peptides that mimic hepcidin activity in mice and may be useful for the treatment of iron overloadLow Serum Hepcidin in Patients with Autoimmune Liver Diseases.Hepcidin modulation in human diseases: from research to clinic.The iron homeostasis network and hepatitis C virus - a new challenge in the era of directly acting antiviralsAlterations in the iron homeostasis network: A driving force for macrophage-mediated hepatitis C virus persistency.Correlation of serum hepcidin levels with disease progression in hepatitis B virus-related disease assessed by nanopore film based assayReduced serum hepcidin levels in patients with chronic hepatitis C.Hepcidin and Its Role in Iron Homeostasis.Hepcidin production in response to iron is controlled by monocyte-derived humoral factors.Pegylated interferon-α induced hypoferremia is associated with the immediate response to treatment in hepatitis C.The serum hepcidin:ferritin ratio is a potential biomarker for cirrhosis.Bone morphogenetic protein-binding endothelial regulator of liver sinusoidal endothelial cells induces iron overload in a fatty liver mouse model.Occurrence and Recurrence of Hepatocellular Carcinoma Were Not Rare Events during Phlebotomy in Older Hepatitis C Virus-Infected Patients.Upregulation of iron regulatory hormone hepcidin by interferon α.Effect of suppressor of cytokine signaling on hepcidin production in hepatitis C virus replicon cells.Hepcidin as a predictor of treatment response in chronic hepatitis C infection.Reply: To PMID 22334511.A high-fat and cholesterol diet causes fatty liver in guinea pigs. The role of iron and oxidative damage.Low hepcidin in liver fibrosis and cirrhosis; a tale of progressive disorder and a case for a new biochemical marker.Short-term histological evaluations after achieving a sustained virologic response to direct-acting antiviral treatment for chronic hepatitis C
P2860
Q26825671-734AD8B0-C8C2-45BD-8EBF-AE5AF5EA096EQ33600034-33B71704-4B45-4857-827F-97027A569AB2Q33766381-359DC2BB-A603-4956-B48A-E7FAC3D44E1AQ33782058-58C93ED7-8C13-4CA6-A9A1-E3CE19221D9EQ34269113-EC780D56-CBD0-488C-B151-1D584744FE64Q34460329-82472AA4-0D7F-4F5E-8C0F-80E4E61A6AA6Q34765478-B981B632-2EF1-4D5E-B0AE-E6EBE62E01D5Q34864591-555A1062-8FDD-4CC3-AB40-C9230EC921AAQ34922542-138263DB-03D6-459B-81BD-5DC3946F9B20Q35538324-AE789924-B83C-4FE6-BF85-B82ECA55E39AQ35578602-FC08207E-66E0-46CD-A388-0115EF2B061BQ35745075-3D1EC48B-B148-4ACB-B540-0CF957C058CEQ37122273-3B604046-D0AD-4CC5-BB29-A1DBF8AB8F47Q37189852-4CFD7DA9-3CC4-4005-A112-60D43A1288E2Q37189857-978510F5-980B-434A-B3AF-D928DB362AF0Q37303512-E13D2855-FAF1-4AEE-BB5F-12F2BE2970ACQ37387659-959421F7-9AB9-4A49-90AA-E08C666C5FC5Q38967420-6D91090D-E455-42CB-BED5-27F57F11D115Q39051483-FC362511-E5AA-489E-ABBD-D1664D9CB7A8Q39396566-7E2FF5A1-ECA9-4A97-AE2D-B85D4D33B485Q39606468-DE897716-21B9-4DC2-AE76-73F48AD08A63Q39641378-1E419766-C38D-4E7E-BFC3-B2C24BFE2752Q39985325-2039F3AA-C7AD-4DC6-8E48-8FA52EB944C1Q42278132-9D61540D-CD86-420E-8E5F-7809385BD89DQ42484442-FBBCDFC1-102B-499A-938A-EF8A2FEB58CDQ47878317-BF3B53DB-3AB5-4E6F-8EE4-A1D31D36074AQ50547019-18FA73FF-4495-4AFE-A7F5-D327DC2381AEQ50975074-43D90272-E2A7-44F4-B2B0-A8200EBF372DQ55438778-C3E9FAD2-F294-4598-B9C3-32DBB5339F79Q58579652-59A2A550-3000-4485-A307-C3C3C7D3B53E
P2860
Patients with chronic hepatitis C achieving a sustained virological response to peginterferon and ribavirin therapy recover from impaired hepcidin secretion.
description
2008 nî lūn-bûn
@nan
2008 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Patients with chronic hepatiti ...... m impaired hepcidin secretion.
@ast
Patients with chronic hepatiti ...... m impaired hepcidin secretion.
@en
type
label
Patients with chronic hepatiti ...... m impaired hepcidin secretion.
@ast
Patients with chronic hepatiti ...... m impaired hepcidin secretion.
@en
prefLabel
Patients with chronic hepatiti ...... m impaired hepcidin secretion.
@ast
Patients with chronic hepatiti ...... m impaired hepcidin secretion.
@en
P2093
P1476
Patients with chronic hepatiti ...... m impaired hepcidin secretion.
@en
P2093
Hideaki Tanaka
Hisao Hayashi
Masahiko Kaito
Masaki Takeo
Motoh Iwasa
Naohisa Tomosugi
Naoki Fujita
Ryosuke Sugimoto
Satoshi Motonishi
Yoshinao Kobayashi
P304
P356
10.1016/J.JHEP.2008.05.014
P577
2008-06-06T00:00:00Z